ES2361650T3 - Inhibidores de proteína quinasa c-met. - Google Patents

Inhibidores de proteína quinasa c-met. Download PDF

Info

Publication number
ES2361650T3
ES2361650T3 ES08835773T ES08835773T ES2361650T3 ES 2361650 T3 ES2361650 T3 ES 2361650T3 ES 08835773 T ES08835773 T ES 08835773T ES 08835773 T ES08835773 T ES 08835773T ES 2361650 T3 ES2361650 T3 ES 2361650T3
Authority
ES
Spain
Prior art keywords
compound
mmol
aliphatic
reaction
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08835773T
Other languages
English (en)
Spanish (es)
Inventor
David Lauffer
Pan Li
Nathan Waal
Kira Mcginty
Qing Tang
Steven Ronkin
Luc Farmer
Dean Shannon
Dylan Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2361650T3 publication Critical patent/ES2361650T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES08835773T 2007-10-03 2008-09-30 Inhibidores de proteína quinasa c-met. Active ES2361650T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97730507P 2007-10-03 2007-10-03
US977305P 2007-10-03

Publications (1)

Publication Number Publication Date
ES2361650T3 true ES2361650T3 (es) 2011-06-21

Family

ID=40512401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08835773T Active ES2361650T3 (es) 2007-10-03 2008-09-30 Inhibidores de proteína quinasa c-met.

Country Status (12)

Country Link
US (1) US8481524B2 (enExample)
EP (1) EP2205589B1 (enExample)
JP (1) JP2010540649A (enExample)
CN (1) CN101990538A (enExample)
AT (1) ATE502935T1 (enExample)
AU (1) AU2008308900A1 (enExample)
CA (1) CA2701124A1 (enExample)
DE (1) DE602008005786D1 (enExample)
ES (1) ES2361650T3 (enExample)
MX (1) MX2010003563A (enExample)
NZ (1) NZ584311A (enExample)
WO (1) WO2009045992A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317277A (zh) 2008-10-21 2012-01-11 沃泰克斯药物股份有限公司 C-met蛋白激酶抑制剂
MX2012007935A (es) 2010-01-07 2012-08-15 Du Pont Compuestos heterociclicos fungicidas.
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP5965499B2 (ja) 2012-12-25 2016-08-03 日本曹達株式会社 ハロゲン化アニリンおよびその製造方法
CN103242216A (zh) * 2013-05-07 2013-08-14 兰州梦唐精细化工有限公司 N- Boc -六氢-5-氧代环戊[C]并吡咯的合成方法
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004284420A1 (en) * 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
US7169781B2 (en) * 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
EP2004625B1 (en) * 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders

Also Published As

Publication number Publication date
WO2009045992A2 (en) 2009-04-09
US8481524B2 (en) 2013-07-09
CN101990538A (zh) 2011-03-23
US20110136789A1 (en) 2011-06-09
NZ584311A (en) 2012-03-30
DE602008005786D1 (de) 2011-05-05
EP2205589A2 (en) 2010-07-14
WO2009045992A3 (en) 2009-06-04
ATE502935T1 (de) 2011-04-15
CA2701124A1 (en) 2009-04-09
EP2205589B1 (en) 2011-03-23
AU2008308900A1 (en) 2009-04-09
JP2010540649A (ja) 2010-12-24
MX2010003563A (es) 2010-06-02

Similar Documents

Publication Publication Date Title
ES2336625T3 (es) Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
ES2361650T3 (es) Inhibidores de proteína quinasa c-met.
US8518938B2 (en) c-MET protein kinase inhibitors
ES2393693T3 (es) Un derivado de triazolotiadiazol como inhibidor de la proteína-quinasa c-Met
TWI491614B (zh) Ｃ－ｍｅｔ蛋白質激酶之胺基吡唑三唑并噻二唑抑制劑
US8263777B2 (en) Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
CN102448968A (zh) C-met蛋白激酶的取代的吡唑抑制剂
HK1151519A (en) C-met protein kinase inhibitors
HK1161257A (en) C-met protein kinase inhibitors
HK1129890B (en) C-met protein kinase inhibitors for the treatment of proliferative disorders